With generic competition for its heart drugs rising due to patent expirations, the company is ditching its large sales force for those drugs. AbbVie is also re-focusing its development efforts away from cardiac medications toward speciality drugs.

AbbVie was spun off from Abbott Laboratories (NYSE:ABT) at the beginning of this year. Abbott Laboratories (NYSE:ABT) retained its medical device, generic medication and diagnostics units. Rheumatoid arthritis drug Humira is AbbVie’s best selling drug, producing sales of $7.93 billion in 2012.